Mutations in the riboflavin biosynthesis pathway confer resistance to furazolidone and abolish the synergistic interaction between furazolidone and vancomycin in Escherichia coli
| dc.contributor.author | Wykes H | |
| dc.contributor.author | Le VVH | |
| dc.contributor.author | Rakonjac J | |
| dc.date.accessioned | 2024-11-19T22:37:26Z | |
| dc.date.available | 2024-11-19T22:37:26Z | |
| dc.date.issued | 2024-07-17 | |
| dc.identifier.doi | 10.1101/2024.07.17.603971 | |
| dc.identifier.elements-type | preprint | |
| dc.identifier.uri | https://mro.massey.ac.nz/handle/10179/72030 | |
| dc.language | English | |
| dc.publisher.uri | https://www.biorxiv.org/content/10.1101/2024.07.17.603971v2 | |
| dc.rights | (c) 2024 The Author/s | |
| dc.rights | CC BY 4.0 | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.title | Mutations in the riboflavin biosynthesis pathway confer resistance to furazolidone and abolish the synergistic interaction between furazolidone and vancomycin in Escherichia coli | |
| dc.type | other | |
| pubs.elements-id | 491094 | |
| pubs.organisational-group | Other |